Skip to main content

Lupus

      Recommend "Triple Therapy" = Glucocorticoids + two other agents

      Practically, that means MMF + belimumumab OR CNI for m

      Mike Putman EBRheum

      10 months 2 weeks ago
      Recommend "Triple Therapy" = Glucocorticoids + two other agents Practically, that means MMF + belimumumab OR CNI for most pts For the CYC afficionados, the lower-dose EUROLUPUS protocol is preferred #ACR24 @RheumNow https://t.co/0gRISXSw0c
      Interesting! Study of pts w/ ANA(-) & dsDNA(+). 1 in 5 dx with APLS! Have others seen that?

      I have been disgregard

      Mike Putman EBRheum

      10 months 2 weeks ago
      Interesting! Study of pts w/ ANA(-) & dsDNA(+). 1 in 5 dx with APLS! Have others seen that? I have been disgregarding this pattern, though some of that is related to my in-house assay (seems overly-sensitive) & my bias against overdiagnosis #ACR24 @RheumNow Abstr#2391 https://t.co/FWgCjEwPDK
      Abstract 1876: Developed a machine learning model w/ #SDoH covariates to accurately identify patients with SLE and ESR

      Akhil Sood MD AkhilSoodMD

      10 months 2 weeks ago
      Abstract 1876: Developed a machine learning model w/ #SDoH covariates to accurately identify patients with SLE and ESRD in NIH All of US dataset @RheumNow #ACR24 https://t.co/TLDSiBZZPs
      Provocative study suggests SLE has changed. Big picture: less physical manifestations, more serologic

      @andreafava why i

      Mike Putman EBRheum

      10 months 2 weeks ago
      Provocative study suggests SLE has changed. Big picture: less physical manifestations, more serologic @andreafava why isn't this just more-testing & more-sensitive testing shifting the phenotype of who we diagnose? #ACR24 @RheumNow Abstr#2413 https://t.co/o2e9TFMsUp
      Lots of data on TYKs including much supporting efficacy in interferon inhibition

      Can we really call interferon signalli

      Mike Putman EBRheum

      10 months 2 weeks ago
      Lots of data on TYKs including much supporting efficacy in interferon inhibition Can we really call interferon signalling a "central" pathway in SLE? Inhibiting it has been modestly successful, at best, and mostly for skin dx #ACR24 @RheumNow Abstr#2434 https://t.co/Q94FQz3gzO
      Class V #Lupus Nephritis usually takes longer to treat. Stay the course if no contraindications and taper steroids! - Dr

      TheDaoIndex KDAO2011

      10 months 2 weeks ago
      Class V #Lupus Nephritis usually takes longer to treat. Stay the course if no contraindications and taper steroids! - Dr A Askanase #ACR24 LN Guidelines @RheumNow https://t.co/4BBuAWi2da
      Cool study investigating differences in nailfold capillaroscopy, jives w/my clinical experience

      Compared to SLE, pts wi

      Mike Putman EBRheum

      10 months 2 weeks ago
      Cool study investigating differences in nailfold capillaroscopy, jives w/my clinical experience Compared to SLE, pts with DM 🔼nailfold changes, 🔼 loop dilation, 🔼hemorrhages #ACR24 @rheumnow Abstr#2404 https://t.co/8N7KNRZet8
      Dr. @karen_kc123 discusses the results of the VITAL study.
      - Long term use of Vit D3 2000IU was safe and decreased the i

      sheila RHEUMarampa

      10 months 2 weeks ago
      Dr. @karen_kc123 discusses the results of the VITAL study. - Long term use of Vit D3 2000IU was safe and decreased the incidence of all autoimmune dses by 22%. - It took a while to work but the effect dissipates once discontinued. @RheumNow #ACR24 @rheumarhyme https://t.co/mnwRsdZ06N
      the predictive value of a positive ANA test—especially in the absence of other clinical symptoms—remains a challenge. A positive test often leads to further testing, yet it does not necessarily indicate whether a patient truly has an underlying autoimmune disease. The development of AI and machine learning algorithms presents an opportunity to interpret autoantibody tests and predict autoimmune diseases. Here are three studies looking at this
      In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #S

      sheila RHEUMarampa

      10 months 2 weeks ago
      In earlier studies of Vit D, there were conflicting evidence as to whether it reduced or increased the risk of RA and #SLE @RheumNow #ACR24 @rheumarhyme https://t.co/PvjjmhHaOd
      Abst#2413 SLE Cohort of > 2900 pts over 50 yrs - Prevalence of proteinuria at the time of SLE dx has not changed over

      TheDaoIndex KDAO2011

      10 months 2 weeks ago
      Abst#2413 SLE Cohort of > 2900 pts over 50 yrs - Prevalence of proteinuria at the time of SLE dx has not changed over the decades. Prevalence of proteinuria also did not change at 5 and 10 yrs after dx. Earlier use of HCQ has not led to a ⬇️in lupus nephritis. @RheumNow #ACRbest
      We know most preexisting autoimmune disease is very mangaeable when checkpoint inhibitors are needed.

      So great to see t

      David Liew drdavidliew

      10 months 2 weeks ago
      We know most preexisting autoimmune disease is very mangaeable when checkpoint inhibitors are needed. So great to see that, in the VA, autoimmune disease pts largely haven't missed out on potentially lifesaving cancer immunotherapy. Keep on reassuring! #ACR24 ABST1985 @RheumNow https://t.co/ApOACBLi4K
      Abst#1493 complete renal response (< 0.5 g/g w/< 10 mg/day pred); renal remission (UPCR < 0.3 g/g w/< 5 mg/d

      TheDaoIndex KDAO2011

      10 months 2 weeks ago

      Abst#1493 complete renal response (< 0.5 g/g w/< 10 mg/day pred); renal remission (UPCR < 0.3 g/g w/< 5 mg/day pred). 60 LN pts followed 3 yrs: 40% CRR & 19% RR. Pts not in CRR/RR had⬇️eGFR w/more decline in eGFR over time. No difference b/t CRR/ RR @rheumnow #ACRbest #ACR24

      ×